Psyence Biomedical (PBM) EBITDA (2023 - 2025)

Psyence Biomedical's EBITDA history runs 3 years deep, the most recent figure standing at -$1.5 million for Q3 2025.

• On a quarterly basis, EBITDA fell 230.0% year-over-year to -$1.5 million in Q3 2025; TTM through Sep 2025 was -$3.8 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$6.2 million, down 70.31% from the prior year.
• EBITDA slipped to -$1.5 million in Q3 2025 per PBM's latest filing, from $1.2 million in the prior quarter.
• Across five years, EBITDA topped out at $1.2 million in Q3 2024 and bottomed at -$3.2 million in Q1 2023.
• The 3-year median for EBITDA is -$856580.5 (2023), against an average of -$946799.2.
• Across the five-year window, EBITDA jumped 668.75% in 2024 and sank 230.0% in 2025, its largest moves.
• Year by year, EBITDA stood at -$204101.0 in 2023, then soared by 668.75% to $1.2 million in 2024, then sank by 230.0% to -$1.5 million in 2025.
• Per Business Quant, the three latest PBM EBITDA figures stand at -$1.5 million (Q3 2025), $1.2 million (Q3 2024), and -$204101.0 (Q3 2023).